S412 Diagnostic Accuracy of the Proton Pump Inhibitor Test in Patients With Gastroesophageal Reflux Disease and Non-Cardiac Chest Pain: A Systematic Review and Meta-Analysis
Abstract
Sara Ghoneim, MD1, Nabil El Hage Chehade, MD2, Jiasheng Wang, MD2, Stephen Ganocy, PhD3, Ehsan Chitsaz, MD2, Ronnie Fass, MD4. University of Nebraska Medical Center, Omaha, NE; MetroHealth Medical Center, Cleveland, OH; University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; Esophageal and Swallowing Center, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.